Is Aducanumab treatment developed to prevent progression of Alzheimer's disease cost-effective in Turkey?
Abstract Background Alzheimer's Disease (AD), the most common type of dementia, is a chronic, progressive, and neurodegenerative brain discomfort that causes the be damage to brain cells. Although there is no definitive treatment for AD, various drug treatments are used to reduce and control th...
Main Authors: | Vahit Yigit, Selin Kalender, Iskender Cetinturk |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-08-01
|
Series: | Cost Effectiveness and Resource Allocation |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12962-023-00463-7 |
Similar Items
-
Cost‐effectiveness of aducanumab to prevent Alzheimer's disease progression at current list price
by: Pranay Sinha, et al.
Published: (2022-01-01) -
Aducanumab—Hope or Disappointment for Alzheimer’s Disease
by: Karolina Wojtunik-Kulesza, et al.
Published: (2023-02-01) -
Is Aducanumab for LMICs? Promises and Challenges
by: Illangage P. C. Gunawardena, et al.
Published: (2021-11-01) -
Aducanumab and lecanemab – two novel antibodies against pathologic species of amyloid beta in the treatment of Alzheimer’s disease
by: Jakub Wojcieszak
Published: (2023-05-01) -
Aducanumab: A new hope in Alzheimer's disease
by: Rouchan Ali, et al.
Published: (2022-09-01)